144 related articles for article (PubMed ID: 7932417)
1. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus.
Drenkard C; Villa AR; Alarcón-Segovia D; Pérez-Vázquez ME
J Rheumatol; 1994 Jun; 21(6):1067-72. PubMed ID: 7932417
[TBL] [Abstract][Full Text] [Related]
2. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.
Ruiz-Irastorza G; Egurbide MV; Ugalde J; Aguirre C
Arch Intern Med; 2004 Jan; 164(1):77-82. PubMed ID: 14718326
[TBL] [Abstract][Full Text] [Related]
3. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
4. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
[TBL] [Abstract][Full Text] [Related]
5. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
[TBL] [Abstract][Full Text] [Related]
6. Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus.
Pérez-Vázquez ME; Villa AR; Drenkard C; Cabiedes J; Alarcón-Segovia D
J Rheumatol; 1993 Mar; 20(3):437-42. PubMed ID: 8478848
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
[TBL] [Abstract][Full Text] [Related]
8. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.
Ward MM; Pyun E; Studenski S
Arch Intern Med; 1996 Jun; 156(12):1337-44. PubMed ID: 8651844
[TBL] [Abstract][Full Text] [Related]
9. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
von Scheven E; Glidden DV; Elder ME
Arthritis Rheum; 2002 Aug; 47(4):414-20. PubMed ID: 12209489
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
11. [Retinal vascular lesions in systemic lupus erythematosus and secondary antiphospholipid syndrome].
Ermakova NA; Alekberova ZS; Reshetniak TM; Kalashnikova LA; Kosheleva NM
Vestn Oftalmol; 2005; 121(5):31-6. PubMed ID: 16274063
[TBL] [Abstract][Full Text] [Related]
12. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
Somers E; Magder LS; Petri M
J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
[TBL] [Abstract][Full Text] [Related]
13. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
Sarzi-Puttini P; Atzeni F; Carrabba M
Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome.
Muñoz-Rodríguez FJ; Reverter JC; Font J; Tàssies D; Cervera R; Espinosa G; Carmona F; Balasch J; Ordinas A; Ingelmo M
Haematologica; 2000 Jun; 85(6):632-7. PubMed ID: 10870121
[TBL] [Abstract][Full Text] [Related]
16. [Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: a report of 3 new cases and a review of the literature].
Blanco Y; Ramos-Casals M; García-Carrasco M; Cervera R; Font J; Ingelmo M
Rev Clin Esp; 1999 Sep; 199(9):586-8. PubMed ID: 10568151
[TBL] [Abstract][Full Text] [Related]
17. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality.
Abu-Shakra M; Urowitz MB; Gladman DD; Gough J
J Rheumatol; 1995 Jul; 22(7):1265-70. PubMed ID: 7562756
[TBL] [Abstract][Full Text] [Related]
18. [Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up].
Reshetniak TM; Alekberova ZS; Kotel'nikova GP; Aleksandrova EN; Mach ES; Radenska-Lopovok SG; Kalashnikova LA; Nasonova VA
Ter Arkh; 2003; 75(5):46-51. PubMed ID: 12847898
[TBL] [Abstract][Full Text] [Related]
19. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.
Cook RJ; Gladman DD; Pericak D; Urowitz MB
J Rheumatol; 2000 Aug; 27(8):1892-5. PubMed ID: 10955329
[TBL] [Abstract][Full Text] [Related]
20. The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays.
Alarcon-Segovia D; Mestanza M; Cabiedes J; Cabral AR
J Rheumatol; 1997 Aug; 24(8):1545-51. PubMed ID: 9263149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
